AGIO

Agios Pharmaceuticals Inc

37.19

Oct 22 • 3:59 PM ET +0.01 (0.03%)

37.19

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: IRON BEAM FULC CRSP VRTX BMY KROS NVO RIGL PFE

| Held by: XBI VTI IWM VB VBK VXF IWN IBB DFAS SCHA

Scroll to Statements

Index	RUT
Market Cap	2.22B
Enterprise Value	1.63B
Income	-411.29M
Sales	98.34M
Book/sh	17.21
Cash/sh	10.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	540
IPO	Jul 24, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	22.58
P/B	2.16
P/C	3.60
P/FCF	-
EV/EBITDA	-
EV/Sales	16.61
Quick Ratio	9.79
Current Ratio	10.22
Debt/Eq	0.03
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-7.01
EPS next Y	-3.77
EPS next Q	-1.25
EPS this Y	19.04%
EPS next Y	34.68%
EPS next 5Y	37.17%
EPS past 3/5Y	-18.95% -8.46%
Sales past 3/5Y	55.97% -
EPS Y/Y TTM	-161.11%
Sales Y/Y TTM	140.58%
EPS Q/Q	12.45%
Sales Q/Q	259.25%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	-2.13% 69.52%

Insider Own	2.42%
Insider Trans	-2.30%
Inst Own	116.69%
Inst Trans	3.85%
ROA	-31.89%
ROE	-34.34%
ROIC	-39.62%
Gross Margin	86.55%
Oper. Margin	-466.78%
Profit Margin	-418.24%
SMA20	13.23%
SMA50	11.53%
SMA200	18.23%
Trades

Shs Outstand	59.60M
Shs Float	58.25M
Short Float	12.04%
Short Ratio	6.41
Short Interest	7.02M
52W High	46.00 -19.15%
52W Low	22.24 67.22%
Volatility	5.55% 4.36%
ATR (14)	1.48
RSI (14)	67.64
Beta	0.65
Rel Volume	0.85
Avg Volume	1.09M
Volume	931,127

Perf Week	15.07%
Perf Month	8.77%
Perf Quarter	2.28%
Perf Half Y	44.48%
Perf YTD	36.63%
Perf Year	-10.90%
Perf 3Y	73.95%
Perf 5Y	-23.40%
Perf 10Y	-24.29%
Recom	1.60
Target Price	45.88
Prev Close	37.18
Price	37.19
Change %	0.03%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-20-26	Reiterated	H.C. Wainwright	Buy	$65 → $50
Nov-24-25	Initiated	Truist	Buy
Nov-20-25	Upgrade	Leerink Partners	Market Perform → Outperform	$34
Nov-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$28
Feb-24-25	Initiated	H.C. Wainwright	Buy	$58
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform	$51
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform	$60 → $56
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight	$41
Nov-17-22	Upgrade	Goldman	Sell → Neutral	$17 → $32
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$33
Dec-03-21	Initiated	BofA Securities	Buy	$54
Jul-30-21	Downgrade	Goldman	Neutral → Sell	$58 → $39
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy	$88
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$50
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral	$64 → $54
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight	$46

Show Previous Ratings

Oct-20-26 08:59AM	A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday (PR Newswire)
Oct-19-26 05:43AM	FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings (Stocktwits) +11.43%
Oct-08-26 07:00AM	Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET (GlobeNewswire)
Jul-30-26 03:02PM	Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ... (GuruFocus.com) -6.46%
06:43AM	Agios Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
06:30AM	Loading…
06:30AM	Agios Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-21-26 10:56AM	Agios scraps sickle cell drug programme on underwhelming Phase II data (Clinical Trials Arena) -6.74%
10:09AM	Why Is AGIO Stock Falling Today? (Stocktwits)
09:53AM	Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move (Investor's Business Daily)
09:39AM	Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO) (InvestorsHub)
08:07AM	Agios scraps sickle cell drug (BioPharma Dive)
07:00AM	Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease (GlobeNewswire)
Jul-07-26 12:16PM	AGIO Stock Hits Over 7-Month Highs FDA Catalyst, Seasonally Strong Q2 Earnings Estimate Drive Optimism (Stocktwits) +17.71%
07:00AM	U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease (GlobeNewswire)
Jun-29-26 07:00AM	Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET (GlobeNewswire)
09:00AM	Loading…
Jun-13-26 09:00AM	Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease (GlobeNewswire)
Jun-01-26 12:26PM	Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib (Proactive)
05:00AM	Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib (GlobeNewswire)
May-29-26 10:26AM	Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO) (InvestorsHub)
07:00AM	Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes (GlobeNewswire)
06:17AM	Allogene CEO to step down; Agios drug fails key test (BioPharma Dive)
May-22-26 10:18AM	Avanzanite Bioscience's Partner Agios Announces PYRUKYND (mitapivat) Approval in the European Union for Adults with Thalassaemia (Business Wire)
09:15AM	Agios' PYRUKYND (mitapivat) Approved in the European Union for Adults with Thalassemia (GlobeNewswire)
May-12-26 09:31AM	Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease (GlobeNewswire)
09:30AM	Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias (GlobeNewswire)
Apr-29-26 06:42AM	Agios Pharmaceuticals: Q1 Earnings Snapshot (Associated Press) +13.10%
06:30AM	Agios Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-20-26 12:19PM	Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock (Investor's Business Daily) -22.97%
10:47AM	Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. (Barrons.com)
10:16AM	Agios Pharmaceuticals stock tumbles 25% after Novo data (Investing.com)
07:00AM	Loading…
Apr-06-26 07:00AM	Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET (GlobeNewswire)
Apr-01-26 09:00AM	Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky (PR Newswire)
Mar-31-26 09:37AM	Agios Pharma Rallies On A Surprise FDA Move In Sickle Cell Disease (Investor's Business Daily) +14.25%
07:00AM	Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA (GlobeNewswire)
Mar-10-26 04:00AM	Serviers $2.5B cancer bet underlines a quick oncology growth strategy (Pharma Voice)
Mar-02-26 09:06PM	Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction (MarketBeat)
07:00AM	Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates (GlobeNewswire)
Feb-13-26 10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
Feb-12-26 02:02PM	Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
07:40AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
06:40AM	Agios Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-05-26 10:00AM	Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-04-26 08:41AM	Williams to Report Q4 Earnings: What Surprise Awaits Investors? (Zacks)
Jan-26-26 07:00AM	Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET (GlobeNewswire)
Jan-19-26 05:19PM	Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory (Insider Monkey)
Jan-14-26 01:16PM	Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline (MarketBeat)
Jan-13-26 07:27AM	Agios Pharmaceuticals outlines 2026 strategic priorities (TipRanks)
Jan-12-26 07:00AM	Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth (GlobeNewswire)
Jan-05-26 07:00AM	Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 (GlobeNewswire)
Dec-26-25 08:42AM	Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? (Zacks)
Dec-25-25 10:39AM	Agios (AGIO) Gets 18.6% Boost from Aqvesme OK (Insider Monkey)
06:05AM	Agios Pharmaceuticals price target raised to $34 from $32 at BofA (TipRanks)
Dec-24-25 12:23PM	Here's Why Shares in Agios Pharmaceuticals Popped Today (Motley Fool) +18.63%
11:05AM	AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label (Zacks)
Dec-23-25 07:45PM	U.S. FDA Approves Agios' AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia (GlobeNewswire)
Dec-09-25 10:24AM	Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date (Zacks)
Dec-08-25 07:00AM	Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia (GlobeNewswire)
Nov-25-25 08:39AM	Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst (Insider Monkey) +7.30%
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks) +9.98%
Nov-19-25 04:22PM	Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged (Investor's Business Daily) -50.89%
01:33PM	Why Shares in Agios Pharmaceuticals Got Crushed Today (Motley Fool)
11:30AM	A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%. (Barrons.com)
07:00AM	Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease (GlobeNewswire)
Nov-03-25 09:01AM	Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition (GlobeNewswire) -7.19%
Oct-31-25 01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
Oct-30-25 04:19PM	Agios Pharmaceuticals Inc (AGIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
07:40AM	Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:36AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-17-25 08:00AM	Agios' PYRUKYND (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia (GlobeNewswire)
Oct-16-25 07:00AM	Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET (GlobeNewswire)
Sep-05-25 10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Sep-04-25 07:00AM	Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND (mitapivat) in Thalassemia (GlobeNewswire) -11.03%
Sep-03-25 11:30AM	Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report? (Zacks)
Aug-29-25 05:00AM	Agios Pharmaceuticals, Inc. (AGIO) Advances Pipeline With Tebapivat, AG-236 in Rare Blood Disorders (Insider Monkey)
Aug-04-25 04:01PM	Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia (GlobeNewswire)
09:46AM	Agios shares drop after report notes deaths of Pyrukynd patients (Investing.com)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
06:36AM	Agios Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-14-25 07:00AM	Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET (GlobeNewswire)
Jul-08-25 07:00AM	Agios Appoints Dr. Jay Backstrom to Board of Directors (GlobeNewswire)
Jun-17-25 01:37PM	Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat's Market Potential (Insider Monkey)
Jun-15-25 05:43AM	H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT (Insider Monkey)
Jun-09-25 08:40AM	Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND in Rare Blood Disorders (Business Wire)
Jun-05-25 11:31AM	Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 11:30AM	Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
May-28-25 07:00AM	Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 (GlobeNewswire)
May-14-25 10:00AM	Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress (GlobeNewswire)
May-09-25 07:00AM	Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 (GlobeNewswire)
May-02-25 07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
07:00AM	Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 (GlobeNewswire)
03:02AM	Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
May-01-25 12:06PM	Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:50AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:47AM	Agios Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SARAH GHEUENS	Officer	Oct 22 '26	Proposed Sale	37.52	500	18,760		Oct 22 04:48 PM
SARAH GHEUENS	Officer	Oct 21 '26	Proposed Sale	37.53	1,489	55,881		Oct 21 05:32 PM
Gheuens Sarah	Chief Medical Officer	Aug 04 '26	Sale	30.48	30,000	914,400	54,645	Aug 06 04:13 PM
SARAH GHEUENS	Officer	Aug 04 '26	Proposed Sale	30.48	30,000	914,283		Aug 04 04:08 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '26	Option Exercise	0.00	8,375	0	88,652	Jul 02 04:03 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '26	Sale	37.56	4,007	150,503	84,645	Jul 02 04:03 PM
Gheuens Sarah	Officer	Jul 01 '26	Proposed Sale	37.56	4,007	150,503		Jul 01 04:08 PM
Ballal Rahul D.	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	15,230	Jun 23 05:25 PM
CAPELLO JEFFREY D	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	10,865	Jun 23 05:24 PM
Foster-Cheek Kaye I	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	10,284	Jun 23 05:23 PM
FOUSE JACQUALYN A	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	154,156	Jun 23 05:22 PM
Ho Maykin	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	19,848	Jun 23 05:21 PM
Owen Adams Catherine	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	10,865	Jun 23 05:21 PM
Scadden David	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	20,419	Jun 23 05:20 PM
Smith Cynthia	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	15,230	Jun 23 05:19 PM
Owen Adams Catherine	Director	Jun 13 '26	Option Exercise	0.00	1,976	0	8,049	Jun 16 04:09 PM
CAPELLO JEFFREY D	Director	Jun 13 '26	Option Exercise	0.00	1,976	0	8,049	Jun 16 04:06 PM
Burns James William	Chief Legal Officer	Apr 02 '26	Option Exercise	0.00	8,500	0	52,586	Apr 06 04:11 PM
Burns James William	Chief Legal Officer	Apr 02 '26	Sale	34.71	3,280	113,849	49,306	Apr 06 04:11 PM
Gheuens Sarah	Chief Medical Officer	Apr 02 '26	Option Exercise	0.00	8,500	0	83,217	Apr 06 04:10 PM
Gheuens Sarah	Chief Medical Officer	Apr 02 '26	Sale	34.71	2,940	102,047	80,277	Apr 06 04:10 PM
Jones Cecilia	Chief Financial Officer	Apr 02 '26	Option Exercise	0.00	8,500	0	58,139	Apr 06 04:08 PM
Jones Cecilia	Chief Financial Officer	Apr 02 '26	Sale	34.71	3,141	109,024	54,998	Apr 06 04:08 PM
Milanova Tsveta	Chief Commercial Officer	Apr 02 '26	Option Exercise	0.00	8,500	0	50,091	Apr 06 04:07 PM
Milanova Tsveta	Chief Commercial Officer	Apr 02 '26	Sale	34.71	3,262	113,224	46,829	Apr 06 04:07 PM
Viswanadhan Krishnan	Chief Corp Dev & Strategy	Apr 02 '26	Option Exercise	0.00	8,100	0	13,241	Apr 06 04:05 PM
Viswanadhan Krishnan	Chief Corp Dev & Strategy	Apr 02 '26	Sale	34.71	2,959	102,707	10,282	Apr 06 04:05 PM
Goff Brian	Chief Executive Officer	Apr 02 '26	Option Exercise	0.00	39,028	0	191,104	Apr 06 04:04 PM
Goff Brian	Chief Executive Officer	Apr 02 '26	Sale	34.71	19,068	661,850	177,604	Apr 06 04:04 PM
Goff Brian	Officer	Apr 02 '26	Proposed Sale	34.19	19,068	651,935		Apr 02 04:09 PM
Jones Cecilia	Officer	Apr 02 '26	Proposed Sale	34.19	3,141	107,391		Apr 02 04:07 PM
Viswanadhan Krishnan	Officer	Apr 02 '26	Proposed Sale	34.19	2,959	101,168		Apr 02 04:05 PM
Milanova Tsveta	Officer	Apr 02 '26	Proposed Sale	34.19	3,262	111,528		Apr 02 04:04 PM
Gheuens Sarah	Officer	Apr 02 '26	Proposed Sale	34.19	2,940	100,519		Apr 02 04:03 PM
Burns James William	Officer	Apr 02 '26	Proposed Sale	34.19	3,280	112,143		Apr 02 04:01 PM
Viswanadhan Krishnan	Chief Corp Dev & Strategy	Mar 05 '26	Option Exercise	0.00	8,100	0	8,100	Mar 09 04:12 PM
Viswanadhan Krishnan	Chief Corp Dev & Strategy	Mar 05 '26	Sale	27.80	2,959	82,260	5,141	Mar 09 04:12 PM
Viswanadhan Krishnan	Officer	Mar 05 '26	Proposed Sale	29.00	2,959	85,811		Mar 05 04:28 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 03 '26	Sale	28.88	5,272	152,255	868	Mar 05 04:08 PM
Goff Brian	Chief Executive Officer	Mar 02 '26	Option Exercise	0.00	39,500	0	170,466	Mar 03 04:17 PM
Goff Brian	Chief Executive Officer	Mar 02 '26	Sale	28.96	18,055	522,873	147,733	Mar 03 04:17 PM
Burns James William	Chief Legal Officer	Mar 02 '26	Option Exercise	0.00	17,586	0	45,249	Mar 03 04:17 PM
Burns James William	Chief Legal Officer	Mar 02 '26	Sale	28.96	5,218	151,113	34,531	Mar 03 04:17 PM
Gheuens Sarah	Chief Medical Officer	Mar 02 '26	Option Exercise	0.00	13,666	0	75,593	Mar 03 04:15 PM
Gheuens Sarah	Chief Medical Officer	Mar 02 '26	Sale	28.96	4,055	117,433	67,608	Mar 03 04:15 PM
Jones Cecilia	Chief Financial Officer	Mar 02 '26	Option Exercise	0.00	16,969	0	50,901	Mar 03 04:14 PM
Jones Cecilia	Chief Financial Officer	Mar 02 '26	Sale	28.96	5,035	145,814	38,800	Mar 03 04:14 PM
Milanova Tsveta	Chief Commercial Officer	Mar 02 '26	Option Exercise	0.00	9,666	0	42,778	Mar 03 04:13 PM
Milanova Tsveta	Chief Commercial Officer	Mar 02 '26	Sale	28.96	2,868	83,057	38,778	Mar 03 04:13 PM
Goff Brian	Officer	Mar 02 '26	Proposed Sale	30.23	18,055	545,803		Mar 02 04:10 PM
Burns James William	Officer	Mar 02 '26	Proposed Sale	30.23	5,218	157,740		Mar 02 04:09 PM
Gheuens Sarah	Officer	Mar 02 '26	Proposed Sale	30.23	4,055	122,583		Mar 02 04:08 PM
Jones Cecilia	Officer	Mar 02 '26	Proposed Sale	30.23	5,035	152,208		Mar 02 04:06 PM
Milanova Tsveta	Officer	Mar 02 '26	Proposed Sale	30.23	2,868	86,700		Mar 02 04:05 PM
Milanova Tsveta	Chief Commercial Officer	Jan 05 '26	Option Exercise	0.00	8,475	0	37,665	Jan 07 04:23 PM
Milanova Tsveta	Chief Commercial Officer	Jan 05 '26	Sale	27.02	2,872	77,601	34,793	Jan 07 04:23 PM
Milanova Tsveta	Officer	Jan 05 '26	Proposed Sale	27.22	2,872	78,176		Jan 05 04:05 PM
Burns James William	Chief Legal Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	34,650	Jan 02 08:18 PM
Burns James William	Chief Legal Officer	Dec 30 '25	Sale	27.09	2,932	79,428	31,718	Jan 02 08:18 PM
Goff Brian	Chief Executive Officer	Dec 30 '25	Option Exercise	0.00	38,278	0	149,333	Jan 02 08:16 PM
Goff Brian	Chief Executive Officer	Dec 30 '25	Sale	27.09	18,703	506,664	136,583	Jan 02 08:16 PM
Gheuens Sarah	Chief Medical Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	67,727	Jan 02 08:15 PM
Gheuens Sarah	Chief Medical Officer	Dec 30 '25	Sale	27.09	2,932	79,428	64,795	Jan 02 08:15 PM
Milanova Tsveta	Chief Commercial Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	32,122	Jan 02 08:15 PM
Milanova Tsveta	Chief Commercial Officer	Dec 30 '25	Sale	27.09	2,932	79,428	29,190	Jan 02 08:15 PM
Jones Cecilia	Chief Financial Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	40,326	Jan 02 08:14 PM
Jones Cecilia	Chief Financial Officer	Dec 30 '25	Sale	27.09	2,932	79,428	37,394	Jan 02 08:14 PM
Goff Brian	Officer	Dec 30 '25	Proposed Sale	27.16	18,703	507,973		Dec 30 04:20 PM
Gheuens Sarah	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:18 PM
Jones Cecilia	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:16 PM
Milanova Tsveta	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:13 PM
Burns James William	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:11 PM
Scadden David	Director	Nov 12 '25	Option Exercise	18.09	200	3,618	17,803	Nov 14 04:04 PM
Scadden David	Director	Nov 12 '25	Sale	43.84	200	8,768	17,603	Nov 14 04:04 PM
Gheuens Sarah	Chief Medical Officer	Nov 11 '25	Option Exercise	25.01	2,454	61,375	64,181	Nov 13 04:08 PM
Gheuens Sarah	Chief Medical Officer	Nov 11 '25	Sale	43.78	2,454	107,436	61,727	Nov 13 04:08 PM
SARAH GHEUENS	Officer	Nov 11 '25	Proposed Sale	43.78	2,454	107,441		Nov 12 10:35 AM
Gheuens Sarah	Chief Medical Officer	Oct 30 '25	Option Exercise	25.01	200	5,002	61,927	Nov 03 04:10 PM
Gheuens Sarah	Chief Medical Officer	Oct 30 '25	Sale	43.81	200	8,762	61,727	Nov 03 04:10 PM
SARAH GHEUENS	Officer	Oct 30 '25	Proposed Sale	43.81	200	8,762		Oct 30 05:02 PM
Gheuens Sarah	Chief Medical Officer	Oct 27 '25	Option Exercise	25.01	3,302	82,583	65,029	Oct 29 04:02 PM
Gheuens Sarah	Chief Medical Officer	Oct 27 '25	Sale	43.92	3,302	145,024	61,727	Oct 29 04:02 PM
SARAH GHEUENS	Officer	Oct 27 '25	Proposed Sale	43.92	3,302	145,028		Oct 27 04:32 PM

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

CEO & DirectorMr. Brian M. Goff M.B.A.

Chief Financial OfficerMs. Cecilia Jones

Pharm.D.Dr. Krishnan Viswanadhan M.B.A.

Chief Legal OfficerMr. James William Burns

Ph.D.Dr. Sarah Gheuens M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGIO

Agios Pharmaceuticals Inc

Upgrade your Finviz experience